InvestorsHub Logo
Followers 42
Posts 2198
Boards Moderated 0
Alias Born 02/10/2014

Re: georgejjl post# 1133

Friday, 09/19/2014 5:42:24 PM

Friday, September 19, 2014 5:42:24 PM

Post# of 2207
This article falls shy on what gilead has in its arsenal. 24 weeks of sofosbuvir and ledipisvir or 12 weeks of both with RIBA clears almost 100% of geno 3s, as well as sofosbuvir and ledipisvir for geno 1s for 12 weeks. However, benitec still has the upper edge in my opinion in that it still has the potential for true pan-geno type, and side effects. I personally feel that the major issue for benitec is not efficacy or safety, but rather manufacturing.

Gilead's trials also includes GS5816 which is hoping to be a pan-geno drug. If effective, benitec may be the only one to give Gilead a run for its money when it comes to hep c. As of right now though, gilead is ruling the roost.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BNTC News